These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31478942)

  • 1. Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma: Impact on Prognosis and Insights Into Tumorigenesis.
    Saijo M; Nakamura K; Ida N; Nasu A; Yoshino T; Masuyama H; Yanai H
    Am J Surg Pathol; 2019 Nov; 43(11):1493-1500. PubMed ID: 31478942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
    Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA
    Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA mismatch repair deficiency and p53 abnormality are age-related events in mixed endometrial carcinoma with a clear cell component.
    Ida N; Nakamura K; Saijo M; Nasu A; Yoshino T; Masuyama H; Yanai H
    Pathol Res Pract; 2021 Apr; 220():153383. PubMed ID: 33676104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
    Fadare O; Parkash V
    Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Classification Outperforms Histologic Classification in Prognostication of High-grade Endometrial Carcinomas With Undifferentiated and Sarcomatous Components.
    Hammer PM; Wang A; Vermij L; Zdravkovic S; Heilbroner L; Ryan E; Geisick RLP; Charu V; Longacre TA; Suarez CJ; Ho C; Jenkins TM; Mills AM; Bosse T; Howitt BE
    Am J Surg Pathol; 2024 Aug; 48(8):953-964. PubMed ID: 38780000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
    Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
    Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas.
    Hoang LN; Ali RH; Lau S; Gilks CB; Lee CH
    Int J Gynecol Pathol; 2014 Sep; 33(5):483-91. PubMed ID: 25083964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
    Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
    Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma.
    Abargel A; Avinoach I; Kravtsov V; Boaz M; Glezerman M; Menczer J
    Int J Gynecol Cancer; 2004; 14(2):354-9. PubMed ID: 15086737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate Receptor Alpha Is Preferentially Expressed in the Carcinoma Component of Endometrial Carcinosarcomas: A Potential Target for Adjuvant Therapy.
    Hanley KZ; Horowitz IR; Gordon A; Meisel J; Khanna N
    Int J Gynecol Pathol; 2021 Sep; 40(5):501-509. PubMed ID: 33323854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
    Costa MJ; Guinee D
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between immunohistochemical staining and clinicopathological findings in endometrial carcinoma.
    Saharti SN; Altaf FJ
    Saudi Med J; 2024 Jun; 45(6):560-564. PubMed ID: 38830650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
    Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
    Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients.
    Kato MK; Yoshida H; Tanase Y; Uno M; Ishikawa M; Kato T
    Pathol Oncol Res; 2021; 27():598550. PubMed ID: 34257552
    [No Abstract]   [Full Text] [Related]  

  • 18. FIGO Grade 3 Endometrioid Adenocarcinomas With Diffusely Aberrant β-Catenin Expression: An Aggressive Subset Resembling Cutaneous Pilomatrix Carcinomas.
    Weisman P; Park KJ; Xu J
    Int J Gynecol Pathol; 2022 Mar; 41(2):126-131. PubMed ID: 33811207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
    Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
    Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.
    Iwasa Y; Haga H; Konishi I; Kobashi Y; Higuchi K; Katsuyama E; Minamiguchi S; Yamabe H
    Cancer; 1998 Feb; 82(3):512-9. PubMed ID: 9452269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.